Skip to Content

Entrectinib Approval Status

  • FDA approved: No
  • Generic name: entrectinib
  • Company: Ignyta, Inc.
  • Treatment for: Neuroblastoma

Entrectinib is a potent, novel, orally available, selective tyrosine kinase inhibitor in development for the treatment of neuroblastoma.

Development Status and FDA Approval Process for entrectinib

Jul 10, 2017Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors
May 15, 2017Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
Apr 17, 2016Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting
Jul  6, 2015Ignyta Announces Collaboration with UCSF For Clinical Trial of Entrectinib
Dec 29, 2014Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation for Entrectinib

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.